Malignant Uterine Corpus Neoplasm — Trials

Malignant Uterine Corpus Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,571 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 411
Recruiting: 227
Ph III recruiting: 25
Growth YoY: +1%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 27.6%
Trials / 1,000 deaths: 50.2 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (168)

clinicaltrialsPublishedShowing 151–161 of 161 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01686126	Improving the Treatment for Women With Early Stage Cancer of the Uterus(feMMe)	active not recruiting	Phase 2	165	Queensland Centre for Gynaecological CancerOTHER_GOV	2	Aug 28, 2024	clinicaltrials
NCT06548763	Oral Topotecan With Toripalimab for Patients With Endometrial Cancer	not yet recruiting	Phase 2	30	Fudan UniversityOTHER	1	Aug 12, 2024	clinicaltrials